Table 1.

Comparison of age and baseline clinical and laboratory data in studied patients groups.

Characteristics	Study Group	Control Group
No. patients	106	105
Age, yrs, mean ± SD^*	52.7 ± 11.3	51.9 ± 10.7
Tender joint count, 28 joints, mean ± SD^*	12.8 ± 3.1	13.1 ± 2.9
Swollen joint count, 28 joints, mean ± SD^*	3.5 ± 1.7	3.4 ± 1.9
Functional disability, mean ± SD^*	1.81 ± 0.3	1.79 ± 0.4
DAS28 score, mean ± SD^*	4.7 ± 0.7	4.6 ± 0.9
RAPID-3 score, mean ± SD^*	7.8 ± 0.5	7.7 ± 0.8
RF-positive^**	51.8%	52.3%
Anti-CCP–positive^**	70.7%	71.4%
Patients taking DMARD^**	75/106 (70.8%)	74/105 (70.4%)
Patients taking bDMARD^**	31/106 (29.2%)	31/105 (25.6%)

↵* Student t test.
↵** Chi-squared test. DAS28: 28-joint Disease Activity Score; RAPID-3: Routine Assessment of Patient Index Data 3; RF: rheumatoid factor; anti-CCP: anticyclic citrullinated peptide antibodies; DMARD: disease-modifying antirheumatic drug; bDMARD: biological DMARD.